13F Holdings
中文EN

CURLF Curaleaf Holdings, Inc.

Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1756770 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-0.9%
TTM net income YoY23.4%
TTM EPS YoY17.9%
Revenue 3-yr CAGR3.7%
Net income 3-yr CAGR—

Margins

Gross margin48.0%
Operating margin1.9%
Net margin-16.1%
FCF margin5.3%
EBITDA margin19.2%

Returns

ROE-22.5%
ROA-7.1%
ROIC (approx.)1.4%
Asset turnover0.44x

Leverage & solvency

Liabilities / assets66.3%
Debt / equity0.66x
Current ratio1.12x
Interest coverage0.47x

Cash quality & payout

Operating cash flow / net income-0.76x
Accruals ratio-12.5%
Payout ratio—
Capex / revenue6.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026-03-312026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312021Q42021-12-31
Income statement
Revenue$352.65M$340.10M—$333.07M$317.86M$310.59M——
Cost of revenue$182.17M$170.19M—$171.27M$157.28M$157.50M——
Gross profit$170.48M$169.91M—$161.79M$160.58M$153.08M——
SG&A expense$131.03M$131.68M—$87.75M$118.51M$111.36M—$100.26M
Operating income$2.94M$4.22M—$2.92M$6.92M$6.25M——
Interest expense———$12.78M$13.57M$13.67M——
Pretax income-$22.86M-$26.31M—-$24.13M-$21.42M-$16.27M——
Income tax$14.51M-$38.78M—$25.36M$32.83M$31.84M——
Net income-$32.72M$12.51M$69.80M-$59.82M-$57.03M-$53.16M-$61.06M—
EBITDA$54.48M$52.83M—$52.54M$55.91M$55.41M——
EPS (basic)-0.120.05——-0.25-0.26——
EPS (diluted)-0.120.05——-0.25-0.26——
Weighted avg. shares (diluted)264.88M270.70M——254.94M252.42M——
Balance sheet
Cash & equivalents$92.39M$94.59M—$89.21M$92.80M$87.75M—$299.33M
Receivables$77.26M$70.61M—$73.86M———$60.43M
Inventory$239.87M$244.72M—$225.02M———$248.15M
Current assets$463.66M$467.80M—$448.62M———$726.62M
PP&E, net$501.06M$505.90M—$520.39M———$525.83M
Goodwill$638.29M$633.02M—$635.12M———$571.65M
Intangibles$940.76M$956.07M—$1.01B———$1.04B
Total assets$2.79B$2.81B—$2.85B———$3.11B
Current liabilities$287.81M$307.11M—$294.31M———$316.24M
Short-term debt$46.05M$41.01M—$35.73M———$1.97M
Long-term debt$583.43M$570.53M—$512.92M———$457.92M
Total debt$629.48M$611.54M—$548.65M———$459.88M
Total liabilities$1.95B$1.95B—$2.01B———$1.44B
Shareholders' equity$847.02M$867.46M$821.11M$756.35M$814.82M$871.29M$814.02M$1.55B
Net debt$537.09M$516.95M—$459.44M———$160.55M
Shares outstanding264.98M264.74M—257.49M———708.34M
Cash flow statement
Operating cash flow$21.10M——$43.02M$47.70M———
Capital expenditure$17.07M——$16.53M$16.11M———
Free cash flow$4.03M——$26.49M$31.59M———
Investing cash flow-$18.73M——-$19.31M-$17.23M———
Financing cash flow-$4.33M——-$28.94M-$25.73M———
Depreciation & amortization$51.54M$48.61M—$49.62M$48.99M$49.16M——
Stock-based compensation$14.04M$10.27M—$12.34M$10.29M$8.48M——
Share buybacks$1.00M———$0———

Free plan shows the latest 8 periods; Pro shows all 11 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.